SCHEMBL4353086

SCHEMBL4353086

CC1(C)CC=C(c2cc(CN3CCN(CCO[Si](C)(C)C(C)(C)C)CC3)ccc2C(N)=O)CC1

nearest known ligand 0.44

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 18/20 0.44
KIT P10721 9/20 0.44
GRM2 Q14416 1/20 0.36
MAP3K7 O43318 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4338955 0.88 CSF1R (0.42) CSF1RKIT
SCHEMBL15418128 0.82 CSF1R (0.46) CSF1RKITGRM2
Trifluoroacetic Acid SCHEMBL4351033 0.80 CSF1R (0.60) CSF1RKITGRM2
SCHEMBL15418301 0.79 CSF1R (0.44) CSF1RKITGRM2
SCHEMBL4343883 0.77 CSF1R (0.41) CSF1RKIT
SCHEMBL15418322 0.77 CSF1R (0.46) CSF1RKIT
SCHEMBL15418490 0.77 CSF1R (0.59) CSF1RKIT
SCHEMBL5653414 0.76 CSF1R (0.60) CSF1RKIT
Hydrochloric Acid SCHEMBL4183938 0.76 CSF1R (0.57) CSF1RKIT
Trifluoroacetic Acid SCHEMBL4342002 0.76 CSF1R (0.60) CSF1RKITGRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452996-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-09-27 US disclosed
EP-2021329-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-04-13 EP disclosed
US-20160046602-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-02-18 US disclosed
US-9221797-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2015-12-29 US disclosed
US-20140148448-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-05-29 US disclosed
US-8674100-B2 Inhibitors of C-FMS kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2014-03-18 US disclosed
EP-2687516-A1 Inhibitors of C-FMS Kinase Janssen Pharmaceutica N.V. (BE) 2014-01-22 EP disclosed
EP-2021329-A1 INHIBITORS OF C-FMS KINASE Janssen Pharmaceutica, N.V. (BE) 2009-02-11 EP disclosed
WO-2007124318-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 WO disclosed
US-20070249649-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249649-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK CSF1R 58/4885KIT 114/4885GRM2 1679/4885
US-20140148448-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK CSF1R 58/4885KIT 114/4885GRM2 1679/4885
US-20160046602-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK CSF1R 58/4885KIT 114/4885GRM2 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.